Deciphera Pharmaceuticals Inc
F:D05
Intrinsic Value
The intrinsic value of one D05 stock under the Base Case scenario is 13.39 EUR. Compared to the current market price of 47.91 EUR, Deciphera Pharmaceuticals Inc is Overvalued by 72%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Deciphera Pharmaceuticals Inc
Loading...
Fundamental Analysis

Revenue & Expenses Breakdown
Deciphera Pharmaceuticals Inc
Balance Sheet Decomposition
Deciphera Pharmaceuticals Inc
Current Assets | 349.9m |
Cash & Short-Term Investments | 272.5m |
Receivables | 32.7m |
Other Current Assets | 44.7m |
Non-Current Assets | 71m |
Long-Term Investments | 26.8m |
PP&E | 36.1m |
Other Non-Current Assets | 8.1m |
Free Cash Flow Analysis
Deciphera Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Deciphera Pharmaceuticals Inc
Revenue
|
174.9m
USD
|
Cost of Revenue
|
-5.3m
USD
|
Gross Profit
|
169.6m
USD
|
Operating Expenses
|
-376.1m
USD
|
Operating Income
|
-206.5m
USD
|
Other Expenses
|
16.1m
USD
|
Net Income
|
-190.4m
USD
|
D05 Profitability Score
Profitability Due Diligence
Deciphera Pharmaceuticals Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
Deciphera Pharmaceuticals Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
D05 Solvency Score
Solvency Due Diligence
Deciphera Pharmaceuticals Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Score
Deciphera Pharmaceuticals Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
D05 Price Targets Summary
Deciphera Pharmaceuticals Inc
Dividends
Current shareholder yield for D05 is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one D05 stock under the Base Case scenario is 13.39 EUR.
Compared to the current market price of 47.91 EUR, Deciphera Pharmaceuticals Inc is Overvalued by 72%.